<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02773147</url>
  </required_header>
  <id_info>
    <org_study_id>2015-004311-20</org_study_id>
    <nct_id>NCT02773147</nct_id>
  </id_info>
  <brief_title>Effect of Vitamin B on Plasma Neurofilament Light Protein (NFL) in HIV-infected Individuals With Increased Plasma Homocysteine</brief_title>
  <official_title>Effect of Vitamin B Substitution on Plasma NFL and Neurocognitive Performance in HIV-infected Individuals With Increased Plasma Homocysteine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Göteborg University</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate if B vitamin substitution have effect on NFL
      (neurofilament light protein) plasma levels and neurocognitive performance in HIV-infected
      individuals with increased plasma homocysteine
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Declining NFL or decreased rate of increase of NFL</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Triobe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyanocobalamin 0,5 mg. Daily for 24 months. Folate 0,8 mg. Daily for 24 months. Pyridoxine 3,0 mg. Daily for 24 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyanocobalamin</intervention_name>
    <arm_group_label>Triobe</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folate</intervention_name>
    <arm_group_label>Triobe</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyridoxine</intervention_name>
    <arm_group_label>Triobe</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The ability to understand and give informed consent to participate.

          2. HIV-1 infected with stable ART &gt; 12 months

          3. Plasma HIV-RNA &lt; 50 copies/ml

          4. Plasma homocysteine ≥ 12 μmol/L (subjects with &lt; 12 μmol/L will be included in the
             analysis of secondary endpoint 3 (see 5.4).

          5. Male or female, age 18 or older.

        Exclusion Criteria:

          1. Treatment with trimethoprim-sulfamethoxazole or methotrexate

          2. Ongoing B6, B12 or folate substitution

          3. Antiepileptic treatment

          4. Small bowel or ventricular resection

          5. Disturbed absorption in small bowel (Mb Crohn, untreated coeliac disease)

          6. Ongoing neurological disease or severe psychiatric disease

          7. Any malignant tumor in the history.

          8. Severe ongoing infection or opportunistic infection

          9. AUDIT &gt; 7 for men and &gt; 5 for women

         10. MADRS &gt; 20

         11. Significant B12 or folate deficiency that indicate substitution (all subjects will be
             offered adequate substitution, they will be included in the analysis of secondary
             endpoint 3 (see 5.4)).

         12. Pregnancy at screening visit, or planning pregnancy during study period is an
             exclusion criteria. (Not due to toxicity of Triobe, but to elevated risk of being
             prescribed B-vitamins outside of trial. If study object gets pregnant during study,
             she can continue the study but must be excluded if she starts treatment with other
             B-vitamin treatment than Triobe.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magnus Gisslén, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Göteborg University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Magnus Gisslén, MD, PhD</last_name>
    <phone>+46313436238</phone>
    <email>magnus.gisslen@infect.gu.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Infectious Diseases, Sahlgrenska university hospital</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magnus Gisslén, MD, PhD</last_name>
      <phone>+46313436238</phone>
      <email>magnus.gisslen@infect.gu.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2016</study_first_submitted>
  <study_first_submitted_qc>May 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2016</study_first_posted>
  <last_update_submitted>December 29, 2017</last_update_submitted>
  <last_update_submitted_qc>December 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin B Complex</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Pyridoxine</mesh_term>
    <mesh_term>Pyridoxal</mesh_term>
    <mesh_term>Vitamin B 6</mesh_term>
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

